MedTrace Logo

Global Hip Dysplasia Registry

NCT04117685 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2024-11-18

No results posted yet for this study

Summary

Developmental dysplasia of the hip (DDH) is the most common hip condition affecting infants and children. DDH represents a spectrum of issues affecting the hip joint - a "ball-and-socket" joint. When the femoral head (the "ball) is seated properly in the acetabulum (the "socket"), the hip is stable and can develop normally. However, when the femoral head is not well-seated, the hip can become unstable or dislocate. This instability or dislocation of the femoral head prevents the hip joint from developing normally during infancy and early childhood. If left undetected or untreated, it can lead to debilitating complications later in life.

Development of a comprehensive, prospective international registry for all infants and children with DDH will provide the potential to impact all infants born, not only in British Columbia, but around the world. The purpose of this initiative is to identify best practices and standardize treatment and management strategies in order to optimize clinical and functional outcomes for patients with DDH. This registry includes targeted specific outcomes that will be investigated, in addition to the general collection of data on all patients diagnosed with any form of DDH up to the age of 10 years.

Conditions

  • Hip Dislocation, Congenital
  • Hip Dysplasia, Congenital, Nonsyndromic
  • Congenital Dysplasia of the Hip
  • Congenital Hip Dislocation
  • Congenital Hip Displacement
  • Congenital Hip Dysplasia
  • Dislocation of Hip, Congenital
  • Dislocation, Congenital Hip
  • Displacement, Congenital Hip
  • Dysplasia, Congenital Hip
  • Hip Displacement, Congenital
  • Hip, Dislocation Of, Congenital

Interventions

OTHER

Observational

All groups will undergo observational data collection. No interventions will be made to patient care.

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Kishore Mulpuri, FRCSC · University of British Columbia

Eligibility

Min Age
1 Minute
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04117685 on ClinicalTrials.gov